{"abstract":"This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the following inventions embodied in the following patent applications, entitled \"CB1 receptor mediating compounds\":","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2015/10/28/2015-27454.html","cfr_references":[],"citation":"80 FR 66015","comment_url":null,"comments_close_on":"2015-11-12","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 12, 2015 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2015-27454","effective_on":null,"end_page":66015,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2015/10/28/2015-27454.xml","html_url":"https://www.federalregister.gov/documents/2015/10/28/2015-27454/prospective-grant-of-exclusive-license-development-of-therapeutics-to-treat-obesity-type-2-diabetes","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2015-27454?publication_date=2015-10-28","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2015-10-28/2015-27454/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":421,"last_updated":"2026-07-26 06:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-10-28/pdf/2015-27454.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2015-27454.pdf?1445950019","publication_date":"2015-10-28","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2015/10/28/2015-27454.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T07:45:33Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":66015,"subtype":null,"title":"Prospective Grant of Exclusive License: Development of Therapeutics To Treat Obesity, Type 2 Diabetes, Fatty Liver Disease, and Liver Fibrosis in Humans","toc_doc":"Development of Therapeutics to Treat Obesity, Type 2 Diabetes, Fatty Liver Disease, and Liver Fibrosis in Humans","toc_subject":"Exclusive Licenses:","topics":[],"type":"Notice","volume":80}